Applied DNA Subsidiary, LineaRx, Inc. Signs Joint Development Agreement with Takis and Evvivax to Develop Linear-DNA Based Anti-Cancer Vaccines
Applied DNA Sciences, Inc. (APDN)
Last applied dna sciences, inc. earnings: 8/10 04:05 pm
Check Earnings Report
US:NASDAQ Investor Relations:
adnas.com/molecular-based-security/investors
Company Research
Source: Business Wire
Collaboration Seeks to Develop PCR-produced Linear DNA as a Safer Expression Vector for Vaccines STONY BROOK N.Y.--(BUSINESS WIRE)-- Applied DNA Sciences Inc. (NASDAQ: APDN) (“Applied DNA” or the “Company”) announced today that LineaRx, Inc. (“LineaRx”), its wholly-owned subsidiary focused on next-generation biotherapeutics, has signed a Joint Development Agreement (the “Agreement”) with Takis S.R.L. and Evvivax S.R.L. (“Takis/Evvivax”), biotechnology companies focused on the discovery and development of DNA based anti-cancer vaccines for the human and animal markets, respectively. Under the terms of the Agreement, LineaRx and Takis/Evvivax will jointly develop linear DNA expression vectors for two of Takis/Evvivax’s anti-cancer vaccine candidates utilizing LineaRx’s linear DNA technology. Linear DNA amplicons carrying the DNA sequences for Takis/Evvivax vaccine candidates will be delivered
Show less
Read more
Impact Snapshot
Event Time:
APDN
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
APDN alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
APDN alerts
High impacting Applied DNA Sciences, Inc. news events
Weekly update
A roundup of the hottest topics
APDN
News
- Applied DNA Sciences, Inc. (NASDAQ: APDN) is now covered by analysts at StockNews.com. They set a "hold" rating on the stock.MarketBeat
- Applied DNA Sciences, Inc. (NASDAQ: APDN) is now covered by analysts at StockNews.com. They set a "hold" rating on the stock.MarketBeat
- Applied DNA Sciences, Inc. (NASDAQ: APDN) is now covered by analysts at StockNews.com. They set a "hold" rating on the stock.MarketBeat
- Applied DNA Sciences, Inc. (NASDAQ: APDN) is now covered by analysts at StockNews.com. They set a "hold" rating on the stock.MarketBeat
- Applied DNA Enters into Agreement with Alphazyme for Scale-Up Manufacturing of its Proprietary Linea(TM) RNAP, Progresses Towards GMP Linea(TM) IVT Production Start [Yahoo! Finance]Yahoo! Finance
APDN
Earnings
- 2/8/24 - Beat
APDN
Sec Filings
- 4/19/24 - Form 8-K
- 4/16/24 - Form 8-K
- 3/21/24 - Form EFFECT
- APDN's page on the SEC website